Specialty pharmacist integration into an outpatient neurology clinic improves pimavanserin access

INTRODUCTION: Access to pimavanserin, the only Parkinson disease–related psychosis treatment approved by the FDA, is restricted by insurance requirements, a limited distribution network, and high costs. Following initiation, patients require monitoring for safety and effectiveness. The primary objec...

Descripción completa

Detalles Bibliográficos
Autores principales: Livezey, Sabrina, Shah, Nisha B., McCormick, Robert, DeClercq, Josh, Choi, Leena, Zuckerman, Autumn D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: College of Psychiatric & Neurologic Pharmacists 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120983/
https://www.ncbi.nlm.nih.gov/pubmed/34026394
http://dx.doi.org/10.9740/mhc.2021.05.187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120983/
https://www.ncbi.nlm.nih.gov/pubmed/34026394
http://dx.doi.org/10.9740/mhc.2021.05.187

Ejemplares similares